.jpg)
A NEW BIOMARKER EXPRESSED IN PANCREATIC BETA CELLS USEFUL IN IMAGING OR TARGETING BETA CELLS
US11243214B2
The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).
Key advantages of the technology Highly specific human beta-cells islet biomarkers Labelled tracers available for non-invasive in vivo imaging of pancreatic beta cell mass by complementary imaging modalities (PET-CT, SPECT-CT, MRI) Probes make targeted delivery of therapeutic agents achievable Optimized labeling procedures of the tracers readily available Commercial interest Potential applications in the following fields: Assessment of remaining beta cells in T1D/T2D to allow decision on the best therapies; Treatment monitoring of diabetes, including islet transplantation or attempts at beta cell regeneration; Development of strategies for targeted delivery of therapeutic agents to pancreatic beta cells.